Our in vivo data indicated that combined treatment of SB265610 with anti-PD-L1 can significantly inhibit HOXA7-mediated KRAS mutant CRC metastasis compared with the control or a single agent alone. The gene discussed is KRAS; the disease is colorectal carcinoma.